| Symbol | CTNM |
|---|---|
| Name | CONTINEUM THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 10578 SCIENCE CENTER DRIVE,SUITE 200, SAN DIEGO, California, 92121, United States |
| Telephone | (858) 333-5280 |
| Fax | — |
| — | |
| Website | https://www.contineum-tx.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001855175 |
| Description | Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California. Additional info from NASDAQ: |
(30% Negative) CONTINEUM THERAPEUTICS, INC. (CTNM) Reports Q2 2026 Financial Results
Read moreContineum Therapeutics Reports First-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones
Read moreLorrain Daniel S. 🔴 sold 4.2K shares of Contineum Therapeutics, Inc. (CTNM) at $13.84 Transaction Date: May 01, 2026 | Filing ID: 029435
Read moreContineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Read moreContineum Therapeutics Reports Positive Topline Data From Its Exploratory PIPE-791 Phase 1b Trial in Chronic Pain
Read moreNew Form DEFA14A - Contineum Therapeutics, Inc. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001628280-26-028895 <b>Size:</b> 1 MB
Read moreNew Form DEF 14A - Contineum Therapeutics, Inc. <b>Filed:</b> 2026-04-30 <b>AccNo:</b> 0001628280-26-028881 <b>Size:</b> 1 MB
Read moreLorrain Daniel S. 🔴 sold 4.2K shares of Contineum Therapeutics, Inc. (CTNM) at $13.43 Transaction Date: Apr 06, 2026 | Filing ID: 023949
Read more📋 DANIEL LORRAIN (Officer) plans to sell 914 shares of CONTINEUM THERAPEUTIC INC (at $13.44 each, total $12K) Filed: Apr 06, 2026 | ID: 003275
Read moreContineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Read more